Epiminder Reaches 25 Enrolled Patients in Epilepsy Study
MT Newswires Live
Jun 01
Epiminder (ASX:EPI) reached 25 enrolled patients in its DETECT (Diagnosing Epilepsy To EffeCT change) clinical study in the US, according to a Monday filing with the Australian bourse.
The study is evaluating the Minder system, an implantable device for continuous monitoring of brain activity, as a tool to improve clinical decision-making for patients with epilepsy after an inconclusive prolonged electroencephalographic monitoring assessment, the filing said.
The company is progressing toward its next enrolment target of 50 patients, expected in the third quarter of the year, and is on track to meet its stated target of 210 patients by the end of the first half of 2027, per the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.